A genetics company committed to providing genetic analysis products and services that translate genomic science into superior solutions for the biomedical research, molecular medicine, agricultural, and non-invasive prenatal testing markets.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
Non-invasive prenatal screening is the future. On top of that:
1) Just closed $130m of financing (no more shareholder dilution required to get to profitability)
2) Rapid growth with international expansion
3) First to market with non-invasive test
4) 2013 FDA approval of low-risk testing
5) As time goes on, more and more insurers will provide coverage
6) Other tests are growing as well (AMD, CF, etc.)
7) Buyout potential